In a research report released this morning, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Neuralstem, Inc. (NYSE MKT:CUR) with an $8.
In a research report issued this morning, Brean Capital analyst Jonathan Aschoff initiated coverage on shares of Neuralstem (NYSE:CUR) with a Buy rating and …
In a research report sent to investors today, H.C.
In a research report issued today, H.C.
